Implementation and benchmarking of a novel analytical framework to clinically evaluate tumor-specific fluorescent tracers.
Marjory KollerSi-Qi QiuMatthijs D LinssenLiesbeth JansenWendy KelderJakob de VriesInge KruithofGuo-Jun ZhangDominic J RobinsonWouter B NagengastAnnelies Jorritsma-SmitBert Van der VegtGooitzen M van DamPublished in: Nature communications (2018)
During the last decade, the emerging field of molecular fluorescence imaging has led to the development of tumor-specific fluorescent tracers and an increase in early-phase clinical trials without having consensus on a standard methodology for evaluating an optical tracer. By combining multiple complementary state-of-the-art clinical optical imaging techniques, we propose a novel analytical framework for the clinical translation and evaluation of tumor-targeted fluorescent tracers for molecular fluorescence imaging which can be used for a range of tumor types and with different optical tracers. Here we report the implementation of this analytical framework and demonstrate the tumor-specific targeting of escalating doses of the near-infrared fluorescent tracer bevacizumab-800CW on a macroscopic and microscopic level. We subsequently demonstrate an 88% increase in the intraoperative detection rate of tumor-involved margins in primary breast cancer patients, indicating the clinical feasibility and support of future studies to evaluate the definitive clinical impact of fluorescence-guided surgery.
Keyphrases
- fluorescence imaging
- clinical trial
- high resolution
- healthcare
- primary care
- photodynamic therapy
- living cells
- randomized controlled trial
- label free
- single molecule
- liquid chromatography
- computed tomography
- acute coronary syndrome
- drug delivery
- positron emission tomography
- quality improvement
- locally advanced
- percutaneous coronary intervention
- study protocol
- fluorescent probe
- pet imaging